explore -WSS

explore

author：leisure time 2025-09-30 12:10:47 - browse：6

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Medicaid rebukes states for mistakenly disenrolling children

explore

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

3 medical device trends to watch in 2024

Feng Zhang CRISPR delivery startup lays off quarter of staff

How generative AI is inspiring dreams of a health data revolution

A rare thyroid diagnosis led to unexpected, all

entertainment

explore

leisure time

Bright Health sells Medicare Advantage business to Molina

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

Medicare details structure of new drug price negotiation program

Why Novartis is changing the name of its research labs

Apple is now the first public company to be valued at $3 trillion

How a scoliosis diagnosis changed the life of one young dancer

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Videos point to link between seizures and unexplained toddler deaths

As demand for Covid shots wanes, Moderna seeks its next success

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

focus

New weight loss drugs work. But how can they best be used?

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

Covid hospitalizations on the rise, Humana says

House transparency, PBM reform bill gains bipartisan support

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

How to protect patients from sexual assault

hotspot

leisure time

explore

leisure time